Front cover image for Transparency in health and health care in the United States : law and ethics

Transparency in health and health care in the United States : law and ethics

This book examines transparency in the health context, including the many ethical and legal issues it raises. It will appeal to anyone interested in how transparency can transform existing health care policy frameworks, from the pharmaceutical industry, to Big Data, to concerns around patient privacy protections.
Print Book, English, 2019
Cambridge University Press, Cambridge, 2019
xv, 356 Seiten : Illustrationen
9781108470995, 9781108456937, 1108470998, 1108456936
Introduction Carmel Shachar, I. Glenn Cohen, Holly Fernandez Lynch and Barbara J. Evans; Part I. Transparency in Health and Health Care: Thematic Issues: Introduction Abigail R. Moncrieff; 1. Smashing into windows: 'the limits of consumer sovereignty in health care' Barry R. Furrow; 2. The interplay of privacy and transparency in health care: the HIPAA privacy rule as a case study Barbara J. Evans; 3. Transparency tradeoffs: priority-setting, scarcity, and health fairness Govind Persad; 4. Slightly hazy: transparency and the costs of too much information Oliver J. Kim; Part II. Transparency and Informed Consent: Introduction Luke Gelinas; 5. Transparency versus informed consent: the patient/consumer paradigms Craig J. Konnoth; 6. Transparency and financial conflicts: the uncertain case for sunshine Richard S. Saver; 7. Making religion transparent: the substance, process, and efficacy of disclosing religious restrictions on care Elizabeth Sepper; Part III. Transparency and Economics: Health Care Costs and Billing: Introduction Kristin M. Madison; 8. Transparency on prescription drug research expenditures: a lever for restraining pricing? Ameet Sarpatwari, Jerry Avorn and Aaron S. Kesselheim; 9. Is pharmaceutical price transparency an effective means to reduce high prices and wide variations? Marc A. Rodwin; 10. Price transparency: a contracts solution Wendy Netter Epstein; 11. Solving surprise medical bills Mark A. Hall; Part IV. Transparency and Innovation: Introduction Holly Fernandez Lynch; 12. Increasing the transparency of FDA review to enhance the innovation process Rachel E. Sachs and Thomas J. Hwang; 13. Transparency and clinical trial data sharing: legal and policy issues Barbara E. Bierer, Mark Barnes and Rebecca Li; 14. The European Medicines Agency's approach to transparency Stefano Marino and Spyridon Drosos; Part V. Transparency and Outcomes: Promoting Health and Safety: Introduction Gregory Curfman; 15. The role of transparency in promoting healthy behaviors: pros, cons, and perils of information sharing to foster personal responsibility in health care Anthony W. Orlando and Arnold J. Rosoff; 16. The role of transparency in patient safety improvement Michelle M. Mello, David M. Studdert, Brahmajee K. Nallamothu and Allen Kachalia; 17. Personal health records as a tool for transparency in health care Sharona Hoffman; 18. Nontransparency in electronic health record systems Jim Hawkins, Barbara J. Evans and Harlan M. Krumholz; 19. Transparency challenges in reproductive health care Dov Fox; Part VI. Challenges in Promoting and Measuring Transparency in Health Care: Introduction I. Glenn Cohen; 20. ERISA as a barrier for state health care transparency efforts Erin C. Fuse Brown and Jaime S. King; 21. Transparency and data sharing in clinical research and Big Pharma Jennifer E. Miller; 22. Promoting IRB transparency: about what, to whom, why, and how? Holly Fernandez Lynch; 23. Using disclosure to regulate PBMs: the dark side of transparency David A. Hyman and William E. Kovacic.